Table 1 Studies assessing the use of CMR in MR with or without echocardiography

From: Assessment of mitral valve regurgitation by cardiovascular magnetic resonance imaging

Study (year)

n

Prospective study?

Correlation (r)a

Bias (ml)b

LVSV – AoPC method

Penicka et al. (2018)13

258

Yes

0.61

17.1 ± 28.9

Heo et al. (2017)44

37

Yes

PISA: 0.81

–15.2 ± 18.3

2D volumetric: 0.56

–17.4 ± 29.4

3D echo: 0.94

8.7 ± 11.6

Harris et al. (2017)45

22

Yes

Sachdev et al. (2017)46

50

Yes

0.79

–0.6 (–43 to 44)

Myerson et al. (2016)12

109

Yes

Aplin et al. (2016)47

72

Yes

0.80

11 ± 28

Lopez-Mattei et al. (2016)48

70

No

0.59

2 ± 17

Uretsky et al. (2015)19

103

Yes

0.60

16 (–38 to 70)

Brugger et al. (2015)49

55

Yes

3D TOE PISA: 0.87

–5.9 (–26.5 to 14.7)

3D TTE PISA: 0.74

–11.8 (–39.4 to 15.8)

Choi et al. (2014)50

52

Yes

2D TTE PISA: 0.84

–10.4 (–29.8 to 8.9)

3D TTE PISA: 0.91

0.9 (–12.8 to 14.7)

Van De Heyning et al. (2013)51

38

Yes

2D TTE Doppler: –0.14

39 (limits not reported)

TTE PISA: 0.45

30 (limits not reported)

Thavendiranathan et al. (2013)52

35

Yes

3D integrated PISA: 0.92

1.4 (–17 to 19.8)

3D peak PISA: 0.87

15.3 (–10.2 to 40.8)

Son et al. (2013)53

32

Yes

2D PISA: 0.55

7.9 (–46.9 to 62.8)

2D VM: 0.58

16.7 (–44.9 to 78.2)

3D FVCD: 0.85

5.7 (–27.9 to 39.3)

Reddy et al. (2013)54

44

Yes

Cawley et al. (2013)55

10

Yes

PISA: 0.96

–4 (–29 to 22)

Doppler: 0.85

21 (–28 to 72)

Hamada et al. (2012)56

46

Yes

EROA: 0.75

20 (–41 to 81)

AROA: –

13 (–22 to 47)

Skaug et al. (2010)57

27

Yes

0.78

–4.7 ± 30.6

Shanks et al. (2010)43

30

Yes

2D TTE: –

–12.4 (–45.6 to 20.8)

3D TEE: –

–2.32 (–18.6 to 13.9)

Myerson et al. (2010)58

55

Yes

Hellgren et al. (2008)59

18

Yes

–27.5 (–65.4 to 10.3)

Gabriel et al. (2008)60

27

Yes

Gelfand et al. (2006)61

107

Yes

Kizilbash et al. (1998)62

22

Yes

0.92

3 ± 13

Hundley et al. (1995)63

17

Yes

LVSV – RVSV method

Sukpraphrute et al. (2012)31

43

No

PISA: 0.48

–6.4 (–49 to 36)

Kon et al. (2004)35

28

No

MVPC – AoPC method

Polte et al. (2017)64

40

Yes

Buck et al. (2008)65

73

Yes

0.63

–13.5 ± 10.3

Fujita et al. (1994)66

19

Yes

4D-flow methods

Kamphuis et al. (2019)67

160

No

Feneis et al. (2018)30

21

No

Direct: 0.81

Indirect: 0.97

Calkoen et al. (2015)37

32

Yes

0.50–0.60

Roes et al. (2009)28

51

No

Marsan et al. (2009)68

64

Yes

3D TTE: 0.94

–0.08 (–7.7 to 7.6)

2D TTE: –

–2.9 (–18 to 12.5)

Westenberg et al. (2008)38

30

No

Other quantitative methods

Gorodisky et al. (2018)69

27

Yes

CMR PISA versus echo PISA: 0.87

Uretsky et al. (2010)70

23

No

Nonquantitative methods

Heitner et al. (2012)71

68

No

0.47

Ozdogan et al. (2009)72

21

No

Buchner et al. (2008)34

35

Yes

CMR EROA versus echo EROA: 0.81

Aurigemma et al. (1990)73

50

Yes

Pflugfelder et al. (1989)74

26

Yes

  1. AoPC, aortic phase-contrast stroke volume; AROA, anatomical regurgitant orifice area; CMR, cardiac magnetic resonance imaging; echo, echocardiography; EROA, effective regurgitant orifice area; FVCD, full-volume colour Doppler echocardiography; LVSV, left ventricular stroke volume; MR, mitral regurgitation; MVPC, mitral valve phase-contrast stroke volume; PISA, proximal isovelocity surface area; RVSV, right ventricular stroke volume; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; VM, volumetric quantification method. aBetween echocardiography-determined and CMR-determined MR volume. bRegurgitant volume (echocardiography – CMR).